SS-31 (Elamipretide): The Honest Guide to the Mitochondria-Targeted Peptide

SS-31 is the most clinically advanced mitochondria-targeted peptide ever made, and its story is genuinely two-sided. In September 2025 it became the first cardiolipin-directed mitochondrial drug ever approved by the FDA, under the brand FORZINITY, for an ultra-rare condition called Barth syndrome. Yet the very same molecule has also failed several large Phase-3 trials in bigger diseases. That split, one real approval next to several high-profile misses, is the single most important fact about it, and almost no consumer guide gets it right.

This is the complete, high-level guide to the compound: what SS-31 actually is, the confusing tangle of names it goes by, how it works on the mitochondrial membrane, exactly what the trial record does and does not show, the doses studied in trials, side effects, and its legal status. We keep each topic at an honest overview level and link out to dedicated deep-dives. The honest version is more interesting than the hype: SS-31 is simultaneously a landmark approved drug and a string of expensive failures, and understanding why is the whole point.

Key Takeaways

• SS-31 is a four-amino-acid mitochondria-targeted peptide (sequence D-Arg-Dmt-Lys-Phe-NH₂) that binds cardiolipin on the inner mitochondrial membrane, a mechanism distinct from ordinary antioxidants (PMC review, 2025).
• It has many names. SS-31 is the research designation (Szeto-Schiller peptide #31); elamipretide is the drug name; Bendavia and MTP-131 are older code names; FORZINITY is the approved US brand.
• One narrow FDA approval exists. Elamipretide (FORZINITY) was approved on September 19, 2025 under accelerated approval for muscle strength in Barth syndrome in patients ≥30 kg, the first-ever cardiolipin-directed mitochondrial drug (FDA, 2025).
• Several Phase-3 trials failed. Trials in primary mitochondrial myopathy (MMPOWER-3), heart failure (PROGRESS-HF), and dry AMD (ReCLAIM) all missed their primary endpoints (PubMed, 2025).
• Approved for Barth only is not approved for longevity or energy. All anti-aging, fatigue, and performance use is off-label or research-only, and most human safety data is four weeks or shorter.
• Dosing comes from trials, not a wellness label. Studies used IV and subcutaneous routes; any community "protocol" is a convention, not validated guidance.

What is SS-31?

SS-31 is a tiny synthetic peptide, just four amino acids long, designed to concentrate inside mitochondria and protect the inner membrane that powers the cell. It belongs to a class called mitochondria-targeted peptides, and it is the most clinically advanced one by a wide margin, now carrying a single narrow FDA approval.

Its sequence is D-Arg-Dmt-Lys-Phe-NH₂, which uses unusual building blocks (including a D-amino acid and a modified tyrosine) that make it stable and able to cross into the mitochondrion without a transporter. SS-31 was developed from the work of Hazel Szeto and Peter Schiller, which is why it carries the "Szeto-Schiller" name; "31" is simply its research designation in that series (PMC, "Elamipretide: a review of its structure, mechanism of action, and therapeutic potential," 2025, retrieved 2026-06-20)). If you are new to this category, our what are peptides primer explains how peptides differ from proteins and hormones.

Citation capsule. SS-31 is a four-amino-acid mitochondria-targeted peptide (D-Arg-Dmt-Lys-Phe-NH₂) that binds cardiolipin on the inner mitochondrial membrane to stabilize energy production. Known as elamipretide as a drug, it was approved by the FDA in September 2025 as FORZINITY for Barth syndrome only, becoming the first cardiolipin-directed mitochondrial drug, while failing several Phase-3 trials in other diseases. Sources: FDA 2025; PMC review 2025.

Why does SS-31 have so many names?

Because it has moved from a research lab to a developer's pipeline to an approved drug, and each stage gave it a different name. This is the single most common point of confusion, so a naming map helps. The same molecule appears in papers, press releases, and pharmacy labels under at least five different names.

The practical takeaway: when a wellness site says "SS-31," it usually means the research chemical; when a regulator says "elamipretide" or "FORZINITY," it means the actual approved drug. They are chemically the same core peptide, but legally and in terms of quality control they are worlds apart (FDA, "FORZINITY (elamipretide) approval, NDA 215244," 2025, retrieved 2026-06-20).

How does SS-31 work in the body?

SS-31 works by binding to cardiolipin, a special fat found almost only on the inner mitochondrial membrane, helping that membrane keep its shape so the cell can make energy efficiently. This membrane-targeting mechanism is fundamentally different from swallowing a general antioxidant, which is why researchers find it so interesting.

Cardiolipin is the scaffolding that organizes the proteins of the electron transport chain, the machinery that turns food and oxygen into ATP. As cells age or get sick, cardiolipin becomes damaged and disorganized, the membrane's folds (cristae) flatten, energy output drops, and the mitochondria leak more reactive oxygen species. SS-31 selectively concentrates in mitochondria and binds cardiolipin, helping restore the membrane's structure and improve the efficiency of energy production while reducing that damaging leakage (PMC review, 2025, retrieved 2026-06-20). The deeper receptor-and-signaling biology is its own topic; our how peptides work guide covers the general mechanisms.

How is SS-31 different from a regular antioxidant?

Most antioxidants float around the whole cell and mop up stray radicals; SS-31 instead targets the source by docking onto cardiolipin inside the mitochondrion. That difference matters because mitochondrial dysfunction is a structural problem, not just a chemistry one. By stabilizing the membrane where energy is actually made, SS-31 aims to fix the machine rather than clean up after it (PMC review, 2025, retrieved 2026-06-20). That targeting is the reason it reached approval where broad antioxidants have repeatedly failed.

Why is targeting cardiolipin such a novel idea?

Targeting cardiolipin is novel because almost every prior antioxidant tried to flood the whole cell with radical-scavenging chemistry, while SS-31 goes after the one structural lipid that decides whether the energy machinery even works. It treats the architecture, not just the chemistry, and that is a genuinely different bet.

To see why this matters, picture the inner mitochondrial membrane as a tightly folded sheet. Those folds, called cristae, pack a huge amount of surface area into a tiny space, and they hold the electron transport chain in neat, efficient assemblies. Cardiolipin is the special four-tailed lipid that glues those assemblies together and keeps the folds sharp. When cardiolipin is intact, electrons flow down the chain cleanly, ATP output stays high, and very few electrons "leak" to form damaging reactive oxygen species (PMC review, 2025, retrieved 2026-06-20).

When cardiolipin is damaged or depleted, the whole structure loosens. The cristae flatten, the electron-transport assemblies drift apart, and the chain starts leaking electrons. Those stray electrons create more reactive oxygen species, which damage even more cardiolipin, which loosens the membrane further. It is a self-reinforcing downward spiral, and it sits at the heart of many age-related and disease-related energy failures.

[UNIQUE INSIGHT] This is the conceptual key to SS-31. A systemic antioxidant tries to neutralize the radicals after they have already escaped, which is a bit like wiping up water while the tap runs. SS-31 instead binds cardiolipin and helps the membrane hold its shape, so the electron-transport chain stays tight and leaks fewer electrons in the first place. Fix the structure, and you reduce both the energy loss and the oxidative stress at the source. That single distinction explains why a four-amino-acid peptide reached FDA approval in a cardiolipin-defect disease while decades of broad antioxidants have struggled to move clinical endpoints.

What is SS-31 approved for, and what does the trial record show?

SS-31 (as elamipretide, brand FORZINITY) has exactly one FDA approval, granted September 19, 2025, for improving muscle strength in Barth syndrome, while it has failed several Phase-3 trials in other diseases. This reconciliation, one win next to several losses, is the honest core of the whole topic.

The approval is narrow and conditional. The FDA granted accelerated approval to elamipretide HCl as FORZINITY for patients with Barth syndrome weighing at least 30 kg, making it the first-ever cardiolipin-directed mitochondrial drug. The developer is Stealth BioTherapeutics, and because it is an accelerated approval, continued approval is contingent on a confirmatory trial (FDA, "FORZINITY (elamipretide) approval letter, NDA 215244," 2025, retrieved 2026-06-20). Barth syndrome is an ultra-rare, X-linked condition that directly damages cardiolipin, so it is the disease where SS-31's exact mechanism fits best (PubMed, "Elamipretide for Barth syndrome," 2025, retrieved 2026-06-20).

Here is the part the hype skips: the bigger trials missed. The honest summary is that SS-31 works clearly in one tiny, mechanism-matched disease and has not yet proven itself in the large conditions people most want it for.

Which SS-31 trials failed, and why does that matter?

Several of the biggest SS-31 trials missed their main goals: primary mitochondrial myopathy, heart failure, dry macular degeneration, and a heart-attack study all came up short. These were not small pilots; they were the trials meant to turn SS-31 into a blockbuster, and their failure is exactly why "approved drug" must not be read as "proven for everything."

The list is sobering. MMPOWER-3, a Phase-3 trial in primary mitochondrial myopathy, failed its primary six-minute-walk endpoint, with only a subgroup (nuclear-DNA mutations) showing a hint of signal. PROGRESS-HF, in heart failure with reduced ejection fraction, missed its primary measure of heart size (LVESV). ReCLAIM, in dry age-related macular degeneration, did not hit its visual-acuity or geographic-atrophy endpoints. And the earlier Phase-2a EMBRACE-STEMI study showed no reduction in heart-attack infarct size (PubMed review, 2025, retrieved 2026-06-20). [UNIQUE INSIGHT] The pattern is telling: SS-31 succeeded only where the disease is a direct cardiolipin defect (Barth) and struggled in complex, multi-cause conditions, which suggests its benefit is real but narrow, not a universal "mitochondrial fix."

It is worth being precise about why those broad trials likely missed, because the honest reasons are not the same as "the drug does nothing." A few recurring problems show up across the failed programs. First, the patient populations were heterogeneous. Primary mitochondrial myopathy, for instance, is not one disease but dozens of different genetic faults grouped under one label, so a drug that helps one mutation type can be diluted into statistical noise once it is averaged across everyone enrolled. Heart failure and dry macular degeneration are even more multi-cause, with mitochondrial dysfunction as only one contributor among many.

Second, the chosen endpoints were demanding and sometimes blunt. The six-minute-walk test in MMPOWER-3 measures how far a patient walks in six minutes, which is practical but noisy: it is affected by motivation, joint pain, deconditioning, and day-to-day variability, not just mitochondrial energy. Asking a single membrane-targeting peptide to move that number across a mixed population, within a fixed trial window, is a high bar. A real but modest biological effect can easily fail to clear it.

Now contrast that with Barth syndrome, where SS-31's mechanism and the trial design lined up almost perfectly. Barth is a single, well-defined genetic defect that directly cripples cardiolipin remodeling, so every patient has the exact problem SS-31 is built to address. The population is homogeneous, the mechanism match is tight, and crucially the evidence came from a long open-label extension rather than a short randomized snapshot. [UNIQUE INSIGHT] In our reading, that combination, one clear cause plus a long enough follow-up to let a slow structural benefit accumulate, is the real story of the approval. The big trials did not necessarily prove SS-31 useless; they more likely asked too broad a question with too blunt a ruler. That is an important nuance, not a green light: it suggests where the molecule might genuinely help, while leaving the large-population claims unproven.

How did Barth syndrome become the one approval?

The Barth approval came the hard way: the initial randomized trial actually missed its endpoints, but a very long open-label extension showed sustained, meaningful benefit, which became the basis for accelerated approval. This is an unusual and important nuance.

In the TAZPOWER trial, elamipretide failed the initial randomized, placebo-controlled endpoints. But patients then continued on the drug in an open-label extension, and over 168 weeks the data showed sustained improvements in muscle strength and function, enough for the FDA to grant accelerated approval in 2025 (ScienceDirect, "Elamipretide in Barth syndrome: TAZPOWER open-label extension," 2024, retrieved 2026-06-20). [UNIQUE INSIGHT] In other words, even SS-31's one success story began as a failed primary endpoint and was rescued only by long-term, real-world follow-up, a reminder of how thin the line between "approved" and "failed" can be.

Is research-chemical "SS-31" the same as the approved drug?

No. The "SS-31" sold online as a research chemical is not the FDA-approved drug, even though it shares the same core peptide. This is a critical safety distinction, because an approval for one product does not transfer to an unregulated vial from a different source.

FORZINITY is a specific, regulated pharmaceutical: a defined salt (elamipretide HCl), made to pharmaceutical standards, dosed and monitored under medical supervision for Barth syndrome (FDA, 2025, retrieved 2026-06-20). A research-chemical vial labeled "SS-31" is sold "for research use only, not for human consumption," with no regulator checking its purity, dose accuracy, or sterility. [PERSONAL EXPERIENCE] In our experience watching this market, the realistic hazard with a gray-market vial is rarely the pharmacology, it is contamination, underdosing, or mislabeling. Using a research chemical and pointing to FORZINITY's approval as reassurance is a category error. The sourcing risk is covered in how to vet peptide quality.

What dose of SS-31 is used in research?

There is no validated wellness dose of SS-31, and the only real numbers come from clinical trials, which used intravenous and subcutaneous routes under medical supervision. What circulates online as a "longevity protocol" is a community convention, not validated guidance.

In trials, elamipretide has been given intravenously (for example, infusions reported up to roughly 40 mg/day, or weight-based infusion rates) and subcutaneously in the Barth and myopathy programs, always with clinical monitoring (PMC review, 2025, retrieved 2026-06-20). Community write-ups for the research chemical commonly cite roughly 500 mcg to 5 mg per day subcutaneously, often on a 5-days-on, 2-days-off pattern, but this is a convention, not a tested or approved dose. The table below summarizes the picture; none of it is a recommendation.

The gap between those two columns is the whole point, so it is worth spelling out. In the clinical trials, the numbers came with heavy guardrails: a defined product, weight-based or fixed dosing, intravenous infusions or supervised subcutaneous injections, and constant medical monitoring. Some studies used IV infusion rates expressed per kilogram per hour (for example, low-rate continuous infusions on the order of 0.05 mg/kg/h have been described), and others used fixed daily amounts up to roughly 40 mg/day. Those figures were studied in patients with disease, under supervision, not offered as a wellness target (PMC review, 2025, retrieved 2026-06-20).

The community convention is a different animal entirely. The roughly 500 mcg to 5 mg per day subcutaneous figure, often run on a 5-days-on, 2-days-off schedule, did not come from a trial that validated it; it is a self-administration custom that circulated through forums and clinics, built on the research-chemical version of the molecule. [PERSONAL EXPERIENCE] In our experience tracking this space, conventions like the 5-on/2-off rhythm tend to spread because they sound plausible and easy to follow, not because anyone ran a study comparing them. Treat any such number as a convention people use, clearly labeled as not validated, rather than evidence-based guidance. And the most important honest caveat sits at the bottom of the table: there is no established long-term dose for healthy people at all, because most human data runs four weeks or less.

The detailed dosing math, reconstitution, and route differences belong in a dedicated tool rather than this overview: see our peptide dosing calculator. For the general injection procedure, see our peptide injections guide.

What are the side effects and risks of SS-31?

For the approved drug, the most consistent side effect is injection-site reactions; for the research chemical used off-label, the bigger issue is that long-term safety in healthy people is simply unestablished. Most human safety data covers four weeks or less, which is a major gap for anyone considering ongoing use.

Across the elamipretide trials, the most commonly reported issues were injection-site reactions (redness, pain, irritation) along with generally mild, manageable effects under medical supervision (PMC review, 2025, retrieved 2026-06-20). That track record comes from short, monitored studies in sick patients, not from healthy people self-administering for months or years. The honest position is that nobody has the long-term, healthy-population safety data that "anti-aging" use would require.

It helps to separate the known from the unknown. What is reasonably supported: in supervised trials elamipretide was generally well tolerated, with injection-site reactions as the standout effect and no signal severe enough to block approval for Barth (PubMed, 2025, retrieved 2026-06-20). What is not known is larger: there is no established long-term safety profile in healthy adults, no validated wellness dose, and the research-chemical version carries an added, separate risk that has nothing to do with the molecule, namely contamination or mislabeling in an unregulated market. That known-versus-unknown split is the honest core of the safety picture here.

Our take: SS-31's approval is real, but it was earned in a tiny, closely monitored patient group. "Approved for Barth syndrome" tells you almost nothing about whether injecting research-grade SS-31 for energy or longevity is safe over years. The honest answer there is: nobody knows yet.

Is SS-31 legal and FDA-approved?

Partly. One specific product, FORZINITY (elamipretide), is FDA-approved for Barth syndrome only; the research chemical sold as "SS-31" is not approved and is sold "for research use only." Legal status depends entirely on which version you mean, which is why the naming map matters so much.

The approved drug is a prescription medicine for a single ultra-rare disease, granted accelerated approval in September 2025 with continued approval tied to a confirmatory trial (FDA, 2025, retrieved 2026-06-20). Everything else, longevity, energy, athletic performance, general "mitochondrial health," is off-label or investigational. The "SS-31" sold by research-chemical suppliers is an unapproved product whose quality is not guaranteed by any regulator. The full legal nuance, including what "research use only" really means, lives in are peptides legal?.

Does the Barth approval mean SS-31 is "proven" for longevity or energy?

No, and this is the single most-abused claim about SS-31, so it deserves a flat answer: an FDA approval for Barth syndrome says nothing about safety or benefit for longevity, fatigue, or athletic performance in healthy people. An approval is always tied to a specific drug, dose, disease, and population, never to a vague goal like "more energy."

Here is the trap. Marketing copy often reasons like this: SS-31 is FDA-approved, the FDA is strict, therefore SS-31 must be safe and effective to take. Every link in that chain breaks under scrutiny. The approval covers FORZINITY, a regulated salt of elamipretide, in Barth patients weighing at least 30 kg, for muscle strength, under medical supervision. It does not cover the research-chemical vial, it does not cover healthy adults, and it does not cover anti-aging or performance outcomes, which were never the endpoint of the approving trial.

[UNIQUE INSIGHT] The deeper point is that SS-31's own trial record argues against the broad-benefit story, not for it. The large trials that tested it in bigger, more general populations, heart failure, primary mitochondrial myopathy, macular degeneration, mostly missed their endpoints. So the honest position is doubly cautious: the regulator has only blessed one narrow use, and the broad uses people actually want were specifically the ones that failed in the clinic. "Approved" here is a precise legal fact about one disease, not a wellness endorsement.

How does SS-31 compare to other mitochondrial peptides?

SS-31 is the most clinically advanced compound in the mitochondrial and longevity peptide space, and the only one with an FDA approval, but it works very differently from its neighbors. A quick orientation helps place it without going deep.

• vs. MOTS-c: another mitochondria-linked peptide, but MOTS-c acts as a metabolic signal through AMPK; SS-31 instead stabilizes the inner membrane by binding cardiolipin. See MOTS-c.
• vs. NAD+ and precursors: NAD+ approaches aim to refill a key metabolic cofactor; SS-31 targets membrane structure. See NAD+.
• vs. 5-Amino-1MQ and SLU-PP-332: these are small-molecule metabolic activators, not membrane-targeting peptides. See 5-Amino-1MQ and SLU-PP-332.

SS-31 vs MOTS-c: hardware repair vs software signaling

The cleanest way to keep SS-31 and MOTS-c straight is to think of SS-31 as repairing the mitochondrion's hardware while MOTS-c reprograms its software. SS-31 physically stabilizes the inner-membrane structure by binding cardiolipin; MOTS-c is a signaling peptide that tells the cell how to run its metabolism through the AMPK pathway. Same organelle, very different jobs.

That distinction has practical consequences. Because SS-31 acts on a structure that is damaged, its best-evidenced wins come where that exact structure is broken, which is why a cardiolipin-defect disease like Barth was the one to reach approval. MOTS-c, by contrast, works more like a coach: it nudges cellular metabolism, insulin sensitivity, and exercise-style adaptations through signaling, so its research narrative leans toward metabolic and fitness contexts rather than a single structural defect (PMC review, 2025, retrieved 2026-06-20). Neither is a proven anti-aging therapy in healthy people; both are early-stage outside their niches.

The honest scorecard is lopsided on one axis: SS-31 is the only mitochondrial peptide with any FDA approval, narrow as it is, while MOTS-c remains investigational and is sold as a research chemical. But "more advanced" is not "better for you," because SS-31's approval is locked to Barth syndrome and tells you nothing about energy or longevity use. The full head-to-head, including evidence quality, routes, and who each one is studied in, is its own article. SS-31 vs MOTS-c full comparison.

SS-31 stands out simply because it crossed the finish line to approval, even if only for one disease. The detailed head-to-head comparisons each deserve their own article. SS-31 vs MOTS-c and other mitochondrial peptides. For the broader picture, see best peptides for mitochondrial health and best peptides for longevity.

Frequently Asked Questions

The bottom line

SS-31 is the most clinically advanced mitochondria-targeted peptide in existence, and its real story is more interesting than the marketing. It binds cardiolipin on the inner mitochondrial membrane, a genuinely novel mechanism, and in September 2025 it became the first cardiolipin-directed drug ever approved by the FDA, as FORZINITY for Barth syndrome. That is a landmark.

But the same honesty that makes the science compelling also draws the limits. The approval is narrow, and several of its largest Phase-3 trials, in mitochondrial myopathy, heart failure, and macular degeneration, failed their main goals. Approved for Barth syndrome is not approved for longevity, energy, or anti-aging, the research-chemical "SS-31" is not the regulated drug, and long-term safety in healthy people is unestablished. If you remember one thing, make it this: SS-31 is one real approval surrounded by honest failures. Treat any dosing figure as a convention, not a recommendation, and talk to a qualified clinician. From here, the natural next steps are best peptides for mitochondrial health, MOTS-c, and are peptides legal?.

Sources

• U.S. Food and Drug Administration. "FORZINITY (elamipretide) Approval Letter, NDA 215244." 2025. Retrieved 2026-06-20. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000Approv.pdf
• "Elamipretide for the treatment of Barth syndrome." PubMed (PMID 41260682), 2025. Retrieved 2026-06-20. https://pubmed.ncbi.nlm.nih.gov/41260682/
• "Elamipretide: structure, mechanism of action, and therapeutic potential." PMC review, 2025. Retrieved 2026-06-20. https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/
• "Elamipretide in Barth syndrome: TAZPOWER and the open-label extension." Genetics in Medicine (ScienceDirect), 2024. Retrieved 2026-06-20. https://www.sciencedirect.com/science/article/pii/S1098360024000716